961 related articles for article (PubMed ID: 28977438)
21. RNA-sequencing of a mouse-model of spinal muscular atrophy reveals tissue-wide changes in splicing of U12-dependent introns.
Doktor TK; Hua Y; Andersen HS; Brøner S; Liu YH; Wieckowska A; Dembic M; Bruun GH; Krainer AR; Andresen BS
Nucleic Acids Res; 2017 Jan; 45(1):395-416. PubMed ID: 27557711
[TBL] [Abstract][Full Text] [Related]
22. Gene activation of SMN by selective disruption of lncRNA-mediated recruitment of PRC2 for the treatment of spinal muscular atrophy.
Woo CJ; Maier VK; Davey R; Brennan J; Li G; Brothers J; Schwartz B; Gordo S; Kasper A; Okamoto TR; Johansson HE; Mandefro B; Sareen D; Bialek P; Chau BN; Bhat B; Bullough D; Barsoum J
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):E1509-E1518. PubMed ID: 28193854
[TBL] [Abstract][Full Text] [Related]
23. Nusinersen ameliorates motor function and prevents motoneuron Cajal body disassembly and abnormal poly(A) RNA distribution in a SMA mouse model.
Berciano MT; Puente-Bedia A; Medina-Samamé A; Rodríguez-Rey JC; Calderó J; Lafarga M; Tapia O
Sci Rep; 2020 Jul; 10(1):10738. PubMed ID: 32612161
[TBL] [Abstract][Full Text] [Related]
24. RNA in spinal muscular atrophy: therapeutic implications of targeting.
Singh RN; Seo J; Singh NN
Expert Opin Ther Targets; 2020 Aug; 24(8):731-743. PubMed ID: 32538213
[TBL] [Abstract][Full Text] [Related]
25. ZPR1 prevents R-loop accumulation, upregulates SMN2 expression and rescues spinal muscular atrophy.
Kannan A; Jiang X; He L; Ahmad S; Gangwani L
Brain; 2020 Jan; 143(1):69-93. PubMed ID: 31828288
[TBL] [Abstract][Full Text] [Related]
26. Restoring SMN Expression: An Overview of the Therapeutic Developments for the Treatment of Spinal Muscular Atrophy.
Aslesh T; Yokota T
Cells; 2022 Jan; 11(3):. PubMed ID: 35159227
[TBL] [Abstract][Full Text] [Related]
27. Plastin 3 Expression Does Not Modify Spinal Muscular Atrophy Severity in the ∆7 SMA Mouse.
McGovern VL; Massoni-Laporte A; Wang X; Le TT; Le HT; Beattie CE; Rich MM; Burghes AH
PLoS One; 2015; 10(7):e0132364. PubMed ID: 26134627
[TBL] [Abstract][Full Text] [Related]
28. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model.
Hua Y; Sahashi K; Hung G; Rigo F; Passini MA; Bennett CF; Krainer AR
Genes Dev; 2010 Aug; 24(15):1634-44. PubMed ID: 20624852
[TBL] [Abstract][Full Text] [Related]
29. hnRNP M facilitates exon 7 inclusion of SMN2 pre-mRNA in spinal muscular atrophy by targeting an enhancer on exon 7.
Cho S; Moon H; Loh TJ; Oh HK; Cho S; Choy HE; Song WK; Chun JS; Zheng X; Shen H
Biochim Biophys Acta; 2014; 1839(4):306-15. PubMed ID: 24533984
[TBL] [Abstract][Full Text] [Related]
30. New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand?
Chen TH
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32392694
[TBL] [Abstract][Full Text] [Related]
31. A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse.
Porensky PN; Mitrpant C; McGovern VL; Bevan AK; Foust KD; Kaspar BK; Wilton SD; Burghes AH
Hum Mol Genet; 2012 Apr; 21(7):1625-38. PubMed ID: 22186025
[TBL] [Abstract][Full Text] [Related]
32. SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy.
Riessland M; Ackermann B; Förster A; Jakubik M; Hauke J; Garbes L; Fritzsche I; Mende Y; Blumcke I; Hahnen E; Wirth B
Hum Mol Genet; 2010 Apr; 19(8):1492-506. PubMed ID: 20097677
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic approaches for spinal muscular atrophy (SMA).
Scoto M; Finkel RS; Mercuri E; Muntoni F
Gene Ther; 2017 Sep; 24(9):514-519. PubMed ID: 28561813
[TBL] [Abstract][Full Text] [Related]
34. 5-(N-ethyl-N-isopropyl)-amiloride enhances SMN2 exon 7 inclusion and protein expression in spinal muscular atrophy cells.
Yuo CY; Lin HH; Chang YS; Yang WK; Chang JG
Ann Neurol; 2008 Jan; 63(1):26-34. PubMed ID: 17924536
[TBL] [Abstract][Full Text] [Related]
35. Combination of SMN trans-splicing and a neurotrophic factor increases the life span and body mass in a severe model of spinal muscular atrophy.
Shababi M; Glascock J; Lorson CL
Hum Gene Ther; 2011 Feb; 22(2):135-44. PubMed ID: 20804424
[TBL] [Abstract][Full Text] [Related]
36. Securinine enhances SMN2 exon 7 inclusion in spinal muscular atrophy cells.
Chen YC; Chang JG; Liu TY; Jong YJ; Cheng WL; Yuo CY
Biomed Pharmacother; 2017 Apr; 88():708-714. PubMed ID: 28152480
[TBL] [Abstract][Full Text] [Related]
37. Nusinersen as a Therapeutic Agent for Spinal Muscular Atrophy.
Li Q
Yonsei Med J; 2020 Apr; 61(4):273-283. PubMed ID: 32233169
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of potential effects of Plastin 3 overexpression and low-dose SMN-antisense oligonucleotides on putative biomarkers in spinal muscular atrophy mice.
Strathmann EA; Peters M; Hosseinibarkooie S; Rigo FW; Bennett CF; Zaworski PG; Chen KS; Nothnagel M; Wirth B
PLoS One; 2018; 13(9):e0203398. PubMed ID: 30188931
[TBL] [Abstract][Full Text] [Related]
39. Temporal and tissue-specific variability of SMN protein levels in mouse models of spinal muscular atrophy.
Groen EJN; Perenthaler E; Courtney NL; Jordan CY; Shorrock HK; van der Hoorn D; Huang YT; Murray LM; Viero G; Gillingwater TH
Hum Mol Genet; 2018 Aug; 27(16):2851-2862. PubMed ID: 29790918
[TBL] [Abstract][Full Text] [Related]
40. Survival motor neuron protein regulates oxidative stress and inflammatory response in microglia of the spinal cord in spinal muscular atrophy.
Ando S; Osanai D; Takahashi K; Nakamura S; Shimazawa M; Hara H
J Pharmacol Sci; 2020 Dec; 144(4):204-211. PubMed ID: 33070839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
